OVID Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States...

Stats
Today's Volume	109 827
Average Volume	210 396
Market Cap	226.27M
EPS	$0 ( 2024-03-11 )
Next earnings date	( $-0.220 ) 2024-05-03
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.32
ATR14	$0.00700 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Levin Jeremy M	Buy	18 248	Common Stock
2024-02-22	Tardio Jason	Buy	168 750	Stock Option (Right to Buy)
2024-02-22	Tardio Jason	Buy	28 125	Common Stock
2024-02-22	Rona Jeffrey A	Buy	28 125	Common Stock
2024-02-22	Rona Jeffrey A	Buy	168 750	Stock Option (Right to Buy)

INSIDER POWER
22.49
Last 96 transactions
Buy: 16 581 029 \| Sell: 7 414 277

Volume Correlation

Long: -0.32 (neutral)

Short: 0.71 (moderate)

Signal:(59.221) Neutral

Ovid Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ovid Therapeutics Inc Correlation - Currency/Commodity

0.21
( neutral )

0.05
( neutral )

0.00
( neutral )

-0.05
( neutral )

Ovid Therapeutics Inc Financials

Annual	2023
Revenue:	$391 695
Gross Profit:	$-1.20M (-307.61 %)
EPS:	$-0.740

Q4	2023
Revenue:	$141 562
Gross Profit:	$-259 830 (-183.55 %)
EPS:	$-0.220

Q3	2023
Revenue:	$108 972
Gross Profit:	$108.97M (100 000.00 %)
EPS:	$-0.160

Q2	2023
Revenue:	$75 000.00
Gross Profit:	$75.00M (100 000.00 %)
EPS:	$-0.180

Financial Reports:

No articles found.

Ovid Therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.